China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates
China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the...
Cancer
Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma
Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...
Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...
Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development
Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...
Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens
Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...
Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...
Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center
Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...
Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program
Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...
AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...
Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial
Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that...
Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE
The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ)...
Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer
Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...
Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors
Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...